Skip to content

The Impact of Simultaneous Presence of Viral and Bacterial Pathogens on Therapy and Course of Severe Pneumonia

The Impact of Simultaneous Presence of Viral and Bacterial Pathogens on Therapy and Course of Severe Pneumonia

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02203110
Acronym
SCAHAVAP
Enrollment
150
Registered
2014-07-29
Start date
2014-01-31
Completion date
2016-03-31
Last updated
2014-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community Acquired Pneumonia, Hospital Acquired Pneumonia, Ventilator Associated Pneumonia

Keywords

simultaneous bacterial and viral pneumonia

Brief summary

The purpose of the study is to determine if the clinical course of pneumonia is more severe when both, bacterial and viral pathogens are find as possible causative agent and how does it affect treatment.

Detailed description

Basic demographic data of the patients (age, gender), data on concomitant diseases and epidemiological circumstances will be collected Severity of illness will be assessed by APACHE II (at day 1) and SOFA (at day 1,2,3 and 7) scoring system Following laboratory tests will be performed at day 1, 2,3 and 7.: * blood count analysis * differential blood count * C- reactive protein, procalcitonin * glucose, urea, potassium, sodium, chloride, magnesium, creatinine, bilirubin, protein, albumin, alkaline phosphatase, aspartate aminotransferase, alanine transaminase, gamma-glutamyl transpeptidase , alpha-amylase, lipase, creatine kinase, lactate dehydrogenase, myoglobin * arterial blood gas analysis * tests of hemostasis. Additional 2 mL of blood will be taken at day 1 and day 21 (or later), due to paired serologic testing To establish the presence of potential pathogens we will perform following microbiological investigations: * cultivation of 2 pairs of blood cultures in all patients * cultivation of sputum or quantitative cultivation of tracheal aspirate in nonintubated patients * quantitative cultivation of tracheal aspirate or bronchoalveolar lavage in intubated patients * testing the presence of soluble Legionella antigen in urine in all patients * testing the presence of genetic material of respiratory viruses (influenza A, influenza B, respiratory syncytial virus , adenovirus, bocavirus, coronavirus, metapneumovirus, parainfluenza virus, rhinovirus) by qualitative polymerase chain reaction (PCR) in nasopharyngeal swabs in all patients, in the tracheal aspirate in nonintubated patients and in tracheal aspirate or bronchoalveolar lavage fluid in intubated patients * testing the presence of mycoplasmal, legionella and chlamydial DNA by qualitative PCR in nasopharyngeal smears in all patients, in the tracheal aspirate in nonintubated patients and in bronchoalveolar lavage fluid or in tracheal aspirate in intubated patients

Interventions

None listed

Sponsors

University of Ljubljana, Faculty of Medicine
CollaboratorOTHER
University Medical Centre Ljubljana
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

diagnosis of * severe community acquired pneumonia or * severe hospital acquired pneumonia or * ventilator--associated pneumonia

Exclusion criteria

* antibiotic treatment of actual episode of pneumonia for more than 24 hours

Design outcomes

Primary

MeasureTime frame
Rate of changes in empirical antibiotic therapy due to broad microbiological diagnosticeach patient will be assessed at enrollment and follow-up for 2 months

Countries

Slovenia

Contacts

Primary ContactPrimoz Karner
primoz.karner@guest.arnes.si+386 51 345616
Backup ContactMatjaz Jereb
matjaz.jereb@kclj.si+386 1 522 8170

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026